Medicine
Imlygic 1000000 PFU/mL injectable suspension
Imlygic 1000000 PFU/mL injectable suspension is a prescription medicine containing Talimogene laherparepvec for intralesional use, marketed by Amgen, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store and transport IMLYGIC at −90°C to −70°C (−130°F to −94°F). Store IMLYGIC…
Key facts
- Active ingredient (INN)
- Talimogene laherparepvec
- Brand
- Imlygic
- Strength
- 1000000 PFU/mL
- Dosage form
- Injectable suspension
- Route
- Intralesional
- Packs
- 1 vial
- Marketing authorisation holder
- Amgen
- Manufacturer
- Amgen
- Origin register
- US FDA, United States
- Storage
- Store and transport IMLYGIC at −90°C to −70°C (−130°F to −94°F). Store IMLYGIC in the carton until use.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XL02 Talimogene laherparepvec
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 November 2015
- Identifiers
- DailyMed set ID 64ffb680-ea8c-42fc-9649-9e8c0eb77ddbNDC 55513-078Application BLA125518
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 1 mL in 1 vial | 55513-078-01 | Amgen | 2 November 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Talimogene laherparepvec
Clinical summary
Talimogene laherparepvec is a prescription medicine indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. It is available as injectable suspension for intralesional use. MedsAcross supplies Talimogene laherparepvec for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Talimogene laherparepvecFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Imlygic prescribing information (Amgen) · U.S. National Library of Medicine, DailyMed
- Imlygic: European public assessment report (EPAR) · European Medicines Agency
Need Imlygic 1000000 PFU/mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.